Journal of Internal Medicine Concepts & Practice ›› 2024, Vol. 19 ›› Issue (03): 201-206.doi: 10.16138/j.1673-6087.2024.03.10

• Review • Previous Articles     Next Articles

Progress in treatment of adult acute lymphoblastic leukemia

LIU Wenhui1, WU Tao1(), ZHANG Xi2   

  1. 1. Department of Hematology, the 940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army, Lanzhou 730050, China
    2. Department of Hematology, Second Affiliated Hospital of Army Medical University of Chinese People’s Liberation Army, Chongqing 400037
  • Received:2023-10-26 Online:2024-06-28 Published:2024-09-09

Abstract:

Acute lymphoblastic leukemia (ALL) is a hematological malignancy with abnormal proliferation of primitive naive lymphocytes and inhibition of normal hematopoiesis. It originates from B-lineage or T-lineage lymphoid progenitor cells, accounting for 20%-30% of adult acute leukemia. Although the complete remission rate of newly diagnosed adult ALL patients after multi-drug combination chemotherapy can reach more than 80%, most of the patients still show relapse and refractory. The 5-year long term survival rate in the patients is only 20%-40% and the clinical characteristics and prognosis are quite different. In recent years, with the advent of targeted drugs, immunotherapy, and chimeric antigen receptor (CAR) -T cell therapy, the clinical outcomes of adult ALL patients have been greatly improved. This article reviews the current progress of new therapeutic drugs for adult ALL in detail.

Key words: Acute lymphoblastic leukemia, Tyrosine kinase inhibitors, Blinatumomab, Inotuzumab ozogamicin, Chimeric antigen receptor T cell, Venetoclax, Nelarabine

CLC Number: